AbbVie Analyst Ratings
AbbVie Analyst Ratings
Strong Financial Outlook and Strategic Initiatives Underpin Buy Rating for AbbVie
Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Aerovate Therapeutics (AVTE)
AbbVie Analyst Ratings
Buy Rating Affirmed: AbbVie's Promising Growth Trajectory and Financial Outlook
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), AbbVie (ABBV) and Establishment Labs Holdings (ESTA)
Daiwa Securities Adjusts Price Target on AbbVie to $171 From $190
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Molina Healthcare (MOH) and Cytokinetics (CYTK)
Hold Rating on AbbVie Amidst Humira Concerns and Biosimilar Competition Despite Strong Pipeline Prospects
AbbVie Analyst Ratings
Barclays Adjusts Price Target on AbbVie to $187 From $195
Analysts' Top Healthcare Picks: AbbVie (ABBV), Wave Life Sciences (WVE)
Buy Rating Affirmed: AbbVie's Strong Performance and Positive Growth Outlook
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), OptimizeRx (OPRX) and AbbVie (ABBV)
Hold Rating on AbbVie Amid Revenue Decline and Profitability Concerns
AbbVie (ABBV) Gets a Buy From Piper Sandler
Hold Rating Maintained for Cerevel Post-Positive Phase 3 Data Amid Pending AbbVie Acquisition
Wells Fargo Reaffirms Their Buy Rating on AbbVie (ABBV)
AbbVie (ABBV) Gets a Buy From Barclays
No Data